Resource Summary Report

Generated by RRID on Sep 8, 2026

Recombinant Anti-PD1 antibody [EPR4877(2)]

RRID:AB_2894867
Type: Antibody

Proper Citation

Abcam Cat# ab137132, RRID:AB_2894867

Antibody Information

URL: http://antibodyregistry.org/AB_2894867

Proper Citation: Abcam Cat# ab137132, RRID:AB_2894867

Target Antigen: PD1

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-P

Antibody Name: Recombinant Anti-PD1 antibody [EPR4877(2)]

Description: This recombinant monoclonal targets PD1

Target Organism: human

Clone ID: EPR4877(2)

Antibody ID: AB_2894867

Vendor: Abcam

Catalog Number: ab137132

Record Creation Time: 20231110T031614+0000

Record Last Update: 20260901T062157+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-PD1 antibody [EPR4877(2)].

No alerts have been found for Recombinant Anti-PD1 antibody [EPR4877(2)].

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Xu Y, et al. (2026) Ultra-precision deconvolution of spatial transcriptomics decodes immune heterogeneity and fate-defining programs in tissues. Nature communications, 17(1).

Naing A, et al. (2026) Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell reports. Medicine, 7(6), 102827.

Pham FK, et al. (2026) Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. Journal for immunotherapy of cancer, 14(6).

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. Cell host & microbe, 34(4), 639.

Schiantarelli J, et al. (2025) Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer cell, 43(2), 308.

Schalck A, et al. (2025) The impact of breast radiotherapy on the tumor genome and immune ecosystem. Cell reports, 44(5), 115703.

Morris VK, et al. (2025) Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(9), 1657.

How JA, et al. (2025) Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med (New York, N.Y.), 6(1), 100494.

Li H, et al. (2025) Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer cell, 43(4), 757.

Cakmak P, et al. (2025) Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures. Immunity, 58(11), 2847.

Mukund K, et al. (2025) Spatially distinct cellular and molecular landscapes define prognosis in triple-negative breast cancer. Cell reports, 45(1), 116752.

Chen Z, et al. (2024) YTHDF2-mediated circYAP1 drives immune escape and cancer progression through activating YAP1/TCF4-PD-L1 axis. iScience, 27(2), 108779.

Lee KJ, et al. (2024) IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy. Cell reports. Medicine, 5(5), 101567.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. Cell genomics, 4(10), 100659.

Campbell MJ, et al. (2024) Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell reports. Medicine, 5(11), 101799.

Tang Z, et al. (2023) Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer. Cell reports. Medicine, 4(2), 100931.

Yadavilli S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer research communications, 3(8), 1564.

Liu Z, et al. (2023) Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer cell, 41(11), 1852.

Huang Q, et al. (2023) MTFR2 shapes a barrier of immune microenvironment in hepatocellular carcinoma. iScience, 26(1), 105095.

Xu-Monette ZY, et al. (2023) Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(23), 4808.